Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US-2024199583-A1 · Jun 20, 2024 · US
US2016264591A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016264591-A1 |
| Application number | US-201415030668-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 20, 2014 |
| Priority date | Oct 21, 2013 |
| Publication date | Sep 15, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are chiral dopants of general formula (I) below as well as uses thereof involving chiral liquid crystal polymers and markings comprising these polymers: wherein R 1 , R 2 , R 3 , R 4 , A 1 and A 2 , m, n, o and p are as defined in the claims.
Opening claim text (preview).
1 . Chiral dopant of general formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently denote C 1 -C 6 alkyl or C 1 -C 6 alkoxy; A 1 and A 2 each independently denote a group: (i) —[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (ii)—C(O)-D 1 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (iii) —C(O)-D 2 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; D 1 denotes a group D 2 denotes a group m, n, o, p, q, r, s, and t each independently denote 0, 1 or 2; y denotes 0, 1, 2, 3, 4, 5 or 6; z equals 0 if y equals 0 and z equals 1 if y equals 1 to 6. 2 . Chiral dopant according to claim 1 , having general formula (IA): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently denote C 1 -C 6 alkyl or C 1 -C 6 alkoxy; A 1 and A 2 each independently denote a group: (i) —[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (ii) —C(O)-D 1 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (iii) —C(O)-D 2 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; D 1 denotes a group D 2 denotes a group m, n, o, p, q, r, s, and t each independently denote 0, 1 or 2; y denotes 0, 1, 2, 3, 4, 5 or 6; z equals 0 if y equals 0 and z equals 1 if y equals 1 to 6. 3 . Chiral dopant according to claim 1 , having general formula (IB): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently denote C 1 -C 6 alkyl or C 1 -C 6 alkoxy; A 1 and A 2 each independently denote a group: (i) —[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (ii) —C(O)-D 1 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (i) —C(O)-D 2 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; D 1 denotes a group D 2 denotes a group m, n, o, p, q, r, s, and t each independently denote 0, 1 or 2; y denotes 0, 1, 2, 3, 4, 5 or 6; z equals 0 if y equals 0 and z equals 1 if y equals 1 to 6. 4 . Chiral dopant according to claim 1 , having general formula (IC): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently denote C 1 -C 6 alkyl or C 1 -C 6 alkoxy; A 1 and A 2 each independently denote a group: (i) —[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (ii) —C(O)-D 1 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (iii) —C(O)-D 2 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; D 1 denotes a group D 2 denotes a group m, n, o, p, q, r, s, and t denote each independently 0, 1 or 2; y denotes 0, 1, 2, 3, 4, 5 or 6; z equals 0 if y equals 0 and z equals 1 if y equals 1 to 6. 5 . Chiral dopant according to claim 1 , having general formula (ID): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently denote C 1 -C 6 alkyl or C 1 -C 6 alkoxy; A 1 and A 2 each independently denote a group: (i) —[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (ii) —C(O)-D 1 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; (iii) —C(O)-D 2 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; D 1 denotes a group D 2 denotes a group m, n, o, p, q, r, s, and t each independently denote 0, 1 or 2; y denotes 0, 1, 2, 3, 4, 5 or 6; z equals 0 if y equals 0 and z equals 1 if y equals 1 to 6. 6 . Chiral dopant according to claim 1 , wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently denote C 1 -C 6 alkyl. 7 . Chiral dopant according to claim 1 , wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently denote C 1 -C 6 alkoxy. 8 . Chiral dopant according to claim 1 , wherein A 1 and A 2 each independently denote —[(CH 2 )y-O]z-C(O)—CH═CH 2 ; R 1 , R 2 , R 3 and R 4 each independently denote C 1 -C 6 alkyl or C 1 -C 6 alkoxy; and m, n, o, and p each independently denote 0, 1, or 2. 9 . Chiral dopant according to claim 1 , wherein A 1 and A 2 each independently denote —C(O)-D 1 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 and/or —C(O)-D 2 -O—[(CH 2 )y-O]z-C(O)—CH═CH 2 ; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , each independently denote C 1 -C 6 alkyl or C 1 -C 6 alkoxy. 10 . Chiral dopant according to claim 1 , wherein the alkyl or alkoxy groups of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently comprise 1, 2, 3, 4, 5 or 6 carbon atoms. 11 . Chiral liquid crystal precursor composition comprising at least one or more chiral dopants according to claim 1 . 12 . Chiral liquid crystal precursor composition according to claim 11 , wherein the composition comprises in addition one or more nematic components. 13 . Chiral liquid crystal precursor composition according to claim 11 containing a security materials selected from inorganic luminescent compounds, organic luminescent compounds, IR-absorbers, magnetic materials, forensic markers, and combinations thereof. 14 . Marking for an item or article, wherein said marking comprises chiral polymeric liquid crystal material wherein the polymer of the chiral polymeric liquid crystal material comprises units derived from one or more chiral dopants according to claim 1 . 15 . Item or article carrying at least one marking according to claim 14 . 16 . Use of a marking according to claim 14 for tracking or tracing an item or article. 17 . Intermediate in the liquid crystal state, obtainable by independently applying a liquid crystal precursor composition comprising a chiral dopant according to claim 1 to a substrate by a variable information printing process or a conventional printing process and applying heat to both evaporate the solvent contained in the liquid crystal precursor composition and promote the liquid crystal state. 18 . An ink, coating or flake comprising one or more nematic compounds and one or more chiral dopants according to claim 1 .
Ortho-condensed systems · CPC title
Physics · mapped topic
characterised by features other than the chemical nature of the binder · CPC title
Heterocyclic compounds · CPC title
from unsaturated acids or derivatives thereof · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.